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Sir,
I read with interest the recent paper by Michlmayr et al, 2010,
describing the effects of neoadjuvant chemotherapy on serum
complement factor expression (Michlmayr et al, 2010). The
authors also reported increase in levels of the plasma protein
inter-a-trypsin inhibitor (IaI), but they may have failed to
appreciate the potential significance of this finding.
IaI is not an acute-phase protein, as the authors report in this
paper; in fact IaI plasma concentration declines during acute
inflammation, because of consumption and decreased liver
expression (Daveau et al, 1993; Opal et al, 2007). Moreover, IaI
heavy chain expression is downregulated in cancers, including
breast cancer (Hamm et al, 2008). Furthermore, IaI does not
simply have hyaluronan-binding properties; it inhibits cancer
metastasis (Werbowetski-Ogilvie et al, 2006; Yagyu et al, 2006)
and has strong anti-inflammatory properties (Zhuo et al, 2004).
In fact, we showed that IaI inhibits complement activa-
tion, both through the classical and the alternative pathways
(Garantziotis et al, 2007). Thus, the association of increased
IaI and complement plasma levels is significant for at least two
reasons. First, upregulation of IaI may be a regulatory mechanism
inhibiting complement activation. As baseline IaI plasma concen-
tration is substantial (0.1–0.5mgml
1; Zhuo et al, 2004), even a
modest relative increase of B50%, as the authors report, would
mean a significant absolute increase. As the observed increase in
plasma IaI overrides the expected acute phase decline, powerful
induction mechanisms may be assumed. Second, IaI is now
in production in the United States and will soon be tested in
a clinical trial for its effect in sepsis morbidity and mortality.
As complement activation appears to have a role in the response
to chemotherapy, factors that affect this activation, such as IaI,
may be interesting as therapeutic agents. Furthermore, IaI levels
may be predictive of response to treatment as well, as they are in
sepsis (Opal et al, 2007).
In conclusion, I believe that IaI–complement interactions are
important in the context of cancer progression and treatment,
and these interactions should be highlighted in reference to the
recently published paper by Michlmayr et al, 2010.
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